Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma
NCT00554788Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- May 2008
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of vincristine sulfate liposome injection, Cisplatin micelle injection (HA132), cyclophosphamide, etoposide, carboplatin and 1 more in retinoblastoma (Rb), sponsored by Children's Oncology Group. Primary endpoint: Event-free Survival at 1 year. Started May 2008; status: completed.
02
Drugs
vincristine sulfate liposome injectionCisplatin micelle injection (HA132)cyclophosphamideetoposidecarboplatin
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT00554788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554788.